H. Suzuki, K. Gen
Mar 1, 2012
Citations
0
Influential Citations
10
Citations
Quality indicators
Journal
Psychiatry and Clinical Neurosciences
Abstract
Aims: Blonanserin is a second‐generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti‐5‐HT2A activity/anti‐D2 activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing.